Related Experiment Videos
Phase II trial of methylprednisolone pulse therapy in childhood chronic thrombocytopenia
Insights
Methylprednisolone (MP) pulse therapy effectively increased platelet counts in children with chronic idiopathic thrombocytopenia (ITP). This treatment offers a safe and rapid therapeutic response for managing ITP in pediatric patients.
Area of Science:
- Pediatric Hematology
- Immunology
- Pharmacology
Background:
- Chronic idiopathic thrombocytopenia (ITP) is an autoimmune disorder characterized by low platelet counts.
- Effective and safe treatment options for pediatric ITP are crucial for managing bleeding risks.
Purpose of the Study:
- To evaluate the efficacy and safety of methylprednisolone (MP) pulse therapy in children with chronic ITP.
- To assess the duration of the therapeutic response and identify potential factors influencing treatment outcomes.
Main Methods:
- A single intravenous course of methylprednisolone (MP), 15 mg/kg/day for 3 consecutive days, was administered to 19 children with chronic ITP.
- Platelet counts were monitored to assess therapeutic response and duration.
- Factors such as age and sex were analyzed for potential correlations with treatment efficacy.
Main Results:
- Approximately 75% of patients experienced a rapid increase in platelet count following MP therapy.
- Ten children maintained platelet counts above 50 x 10(9)/L for over one month.
- Eight children sustained safe platelet counts for four months post-treatment, with no severe adverse effects reported.
- Older children and possibly females showed a more pronounced improvement in platelet count.
Conclusions:
- Three-day methylprednisolone (MP) pulse therapy is a safe and effective treatment for pediatric chronic ITP.
- This therapeutic approach shows promise for managing acute bleeding episodes in children with ITP.
- MP therapy provides a rapid and sustained increase in platelet count, improving patient outcomes.
Abstract:
Nineteen children with chronic idiopathic thrombocytopenia (ITP) were treated with a single intravenous injection of methylprednisolone (MP), 15 mg/kg/day, for 3 consecutive days. The 3-day pulses gave rise to a positive and fast therapeutic response with increase of the platelet count in about three quarters of the patients. The platelet count remained above 50 X 10(9)/1 for more than 1 month in 10 children. Eight out of them still presented a safe platelet count (greater than 50 X 10(9)/1) 4 months after the onset of the therapy. The MP therapy improved the platelet count more in the older children and possibly in the females. No severe side effects were observed. Our results suggest that this therapeutic approach could be useful in the management of acute bleeding episodes in children with chronic ITP.